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Alarming numbers about psychiatric disorders for the next de-
cades have been forecasted by the world health organization (WHO). 
The estimation is that until 2030 four persons in ten retired from their 
jobs will do it due to a psychiatric disorder. In addition, whilst rising 
attention and funding have been given to treatment and research of 
cardiac diseases, cancers and diabetes, the same does not occur for 
psychiatric illnesses. On the contrary, in Brazil psychiatric clinics have 
been closed and health insurance companies have even been classify-
ing psychiatric treatments as non-essential. Biological evolution has 
not followed social evolution leading to the development of several 
modern diseases, including psychiatric disorders. Since medicine 
aims for the improvement of human life, it is important that medical 
research target both, physical and mental health.
Schizophrenia is not only one of the most intriguing psychiatric 
disturbances, but probably the most complex one to be studied. This 
is due to the diverse array of presented symptoms and their overlap 
with those from different psychiatric disorders. As importantly, the 
multifactorial characteristic of schizophrenia, which is based in 
molecular and environmental factors, makes it difficult the estab-
lishment of pre-clinical models. Consequently, their validation has 
been controversial. 
The pathobiology of schizophrenia has been largely investi-
gated in the past years. Scientific articles have been published about 
fundamental knowledge, pre-clinical and clinical aspects and even 
research involving stem cells, denoting crescent efforts and scientific 
interest in the field. However, some of the most elementary features 
of schizophrenia pathogenesis were still not resolved. While basic 
molecular elements have been well characterized, there is still a lack 
of data integrating these results. Schizophrenia diagnosis is strictly 
clinic and prognostic intervention is almost inexistent. Medication 
effects must be more characterized in order to promote more effec-
tive treatment, excluding undesirable side effects as well as providing 
targeted treatment for each particular patient according to their 
stratification status. The moment shows us that there is a need to 
invest more efforts to connect the molecular aspects of schizophrenia. 
With this in mind, Revista de Psiquiatria Clínica offers this spe-
cial edition about “Molecular studies in schizophrenia”. This edition 
is composed by eight articles from research groups from different 
countries ranging from basic science, passing through preclinical 
models up to biomarkers identification. Our intention is to deliver 
knowledge about the newest approaches on schizophrenia and psy-
chiatric research, aiming to generate to our readers new ideas and in-
spire new projects which may add pieces to the schizophrenia puzzle.
